Table 3 Total lifetime cost, life years, and QALYs for PAH patients in FC II and FC III receiving sildenafil and beraprost
From: Economic evaluation of sildenafil for the treatment of pulmonary arterial hypertension in Indonesia
| FC II | FC III | ||||
|---|---|---|---|---|---|
| beraprost | sildenafil | beraprost | sildenafil | ||
| Total lifetime cost (USD) | 35,863 | 37,632 | 30,807 | 35,059 | |
| Life Years | |||||
| No discount | 26.75 | 27.91 | 23.03 | 25.99 | |
| Discount | 16.23 | 16.94 | 14.10 | 15.80 | |
| QALYs | |||||
| No discount | 19.66 | 20.56 | 16.64 | 19.09 | |
| Discount | 11.90 | 12.47 | 10.08 | 11.58 | |